ADC Therapeutics Seeks To Leave Switzerland For Delaware, Converting Every Share One-For-One
The lymphoma-drug maker says holders keep the same share count and its NYSE listing, but Swiss tax rulings must come first.
ADC Therapeutics, which develops cancer drugs called antibody drug conjugates, filed to move its incorporation from Switzerland to Delaware, turning each CHF 0.08 par share into one $0.10 par share of ADC Therapeutics, Inc. The company says the switch would cut duplicate compliance costs and make it easier to issue shares, though it depends on Swiss tax rulings it has not yet obtained.
One share in, one share out
Holders would own the same number of shares after the move as before, and the company says the change does not dilute their economic interest. It also says the business, capitalization and financial statements would stay substantially the same, so the filing includes no pro forma financials. The directors and executive officers are expected to be the same people.
The common stock is listed on the NYSE as ADCT, and the company expects the Delaware shares to trade there under the same symbol. The stock closed at $1.54 on Monday, the session before the plan was announced, and at $1.55 on Tuesday, for a market value of about $197 million.
The board unanimously recommends approval. The reincorporation and charter proposals each need two-thirds of votes represented and a majority of the par value represented. Approval lapses if the company has not become a Delaware corporation by June 30, 2027.
Why the board wants Delaware
The company has been subject to U.S. domestic-company rules since January 1, 2024, so it files U.S. reports alongside Swiss-law ones. The board's case includes lower regulatory costs, closer alignment with its U.S. operations, more room to issue shares for capital raises and deals, and an end to any risk of being a passive foreign investment company, a U.S. tax status.
ADC Therapeutics sells ZYNLONTA, approved for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy, with U.S. accelerated approval and conditional approvals elsewhere. It is headquartered in Switzerland and would move its principal offices to New Providence, New Jersey.
The Swiss tax hurdle
Swiss tax law treats the move as a liquidation, so 35% withholding tax could in principle apply to the amount by which the equity's fair market value exceeds share capital plus confirmed capital-contribution reserves. The company does not expect any tax to be due, because its market value is far below that threshold. If the tax were levied and not recovered from shareholders, the effective rate on the taxable amount would be about 53.8%.
The company still needs advance rulings from the Swiss Federal Tax Administration and the Vaud cantonal tax administration. Other conditions include a creditor-claims process confirmed by a Swiss audit expert, a Lex Koller ruling on foreign-ownership rules, SEC effectiveness of the registration statement and NYSE listing approval. The shareholder meeting is set for 2027, with the date left blank.
If the conditions are not met by June 30, 2027, the move will not happen, and ADC Therapeutics would remain a Swiss company with holders keeping their common shares.